AbbVie Offers Growth, Altria Offers Income: The Dividend Trade-Off

AbbVie and Altria offer two very different dividend propositions. AbbVie yields less but is replacing lost Humira sales with fast-growing medicines. Altria pays far more today, while relying on pricing, cost control and oral nicotine to offset a long decline in cigarette volumes.

AbbVie's growth engine is working

AbbVie's second-quarter 2026 results showed global Skyrizi revenue of $5.51 billion and Rinvoq revenue of $2.53 billion. The two medicines helped its immunology portfolio grow 15.1% on a reported basis even as Humira revenue fell under biosimilar competition.

The company updated full-year adjusted earnings guidance to $13.87 to $14.07 after including acquisition-related costs. A later update in the source article lowered the range by another $0.11 per share to reflect acquired research and milestone expense. Those charges buy pipeline assets, but they also show that replacing Humira requires capital.

AbbVie's dividend used about 66% of trailing free cash flow through June in the source analysis. That is a healthier current cushion than Altria's 78%, although AbbVie's payout has consumed a larger share of cash flow since 2022 as free cash flow declined and dividends increased.

Altria starts with much more income

Altria raised its quarterly dividend to $1.11 in August, an annualized $4.44 per share. The company said that equaled a 6.4% yield at its August 26 closing price. Its long-term policy targets a payout near 80% of adjusted diluted earnings.

First-half adjusted earnings per share grew 4.9%, and management narrowed 2026 guidance to a range consistent with modest growth. That pace can support measured dividend increases if cigarette pricing and newer nicotine products offset volume pressure.

The risk is concentrated. Altria's core cigarette business continues to shrink, and oral nicotine must scale without destroying the economics that fund the dividend. AbbVie faces patent, trial and acquisition risk, but its revenue base is spread across immunology, neuroscience, oncology and aesthetics.

Choosing the right return profile

For an investor prioritizing current income, Altria's yield advantage is difficult to overcome through AbbVie's faster dividend growth alone. For an investor seeking a larger chance of earnings and capital appreciation, AbbVie's lower payout burden and growth products are more attractive.

Neither choice is purely about yield. Altria is a cash-distribution story with a declining core category. AbbVie is a reinvestment story whose dividend depends on successful replacement products. The better stock depends on whether an investor values income now or a wider set of growth options over the next decade.